CRISPR Therapeutics AG — Director's Dealing 2018

Apr 25, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-04-20

Reporting Person: Versant Venture Capital IV, L.P. (10% Owner)
Reporting Person: Versant Side Fund IV, L.P. (10% Owner)
Reporting Person: Versant Ventures IV, LLC (10% Owner)
Reporting Person: Versant Venture Capital V, L.P. (10% Owner)
Reporting Person: Versant Affiliates Fund V, L.P. (10% Owner)
Reporting Person: Versant Ophthalmic Affiliates I, L.P. (10% Owner)
Reporting Person: Versant Venture Capital V (Canada), LP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-20	Common Shares	J	497053	$0.00	Disposed	2238979	Indirect
2018-04-20	Common Shares	J	2947	$0.00	Disposed	13277	Indirect
2018-04-20	Common Shares	J	92918	$0.00	Acquired	92918	Indirect
2018-04-20	Common Shares	J	92918	$0.00	Disposed	0	Indirect
2018-04-23	Common Shares	S	89628	$50.66	Disposed	1539576	Indirect
2018-04-23	Common Shares	S	2630	$51.00	Disposed	45171	Indirect
2018-04-23	Common Shares	S	2915	$51.00	Disposed	50072	Indirect
2018-04-23	Common Shares	S	6821	$50.66	Disposed	117173	Indirect

Footnotes

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners.

F2: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners.

F4: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein.

F5: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV.

F6: The shares are held by VV IV.

F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members.

F8: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V").

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F10: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.

F11: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V").

F12: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.

F13: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA").

F14: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.

F15: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.
("VVC CAN").

F16: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.